DOCS — Doximity, Inc.

Doximity Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $169 million, a 23% year-over-year increase, exceeding guidance by 7%.
• Adjusted EBITDA: $101 million, representing a 60% margin, up from 56% in the prior year; 32% year-over-year growth.
• Free Cash Flow: Increased by 37% year-over-year to $91.6 million.
• Net Revenue Retention Rate: 118% on a trailing 12-month basis.
• Customer Growth: 121 customers contributing over $500,000 each in subscription revenue, up 16% from the previous year.

2. Strategic Updates and Business Highlights

• Network Growth: Record engagement with over 650,000 unique prescribers using workflow tools; significant growth in AI tools with a 50% increase in quarterly active prescribers.
• Product Innovations: Launched the "Ask DoxGPT" feature, integrating Pathway's medical data set and AI models into DoxGPT, enhancing the platform's capabilities.
• Acquisition of Pathway: Fully integrated into DoxGPT, providing unique features such as instant peer-reviewed drug references and access to over 2,000 medical journals without paywalls.
• Integrated Programs: 40% of Q2 bookings came from AI-optimized integrated offerings, up from 5% the previous year, indicating a shift towards more strategic upsell cycles.

3. Forward Guidance and Outlook

• Q3 2026 Revenue Guidance: Expected to be between $180 million and $181 million, representing 7% growth at the midpoint.
• Full Fiscal Year 2026 Revenue Guidance: Revised to $640 million to $646 million, indicating 13% growth at the midpoint.
• Adjusted EBITDA Guidance: Expected between $351 million and $357 million, maintaining a margin of over 55%.
• Market Positioning: Strong client engagement and product momentum, with expectations for continued growth despite potential uncertainties in budget allocations due to policy changes.

4. Bad News, Challenges, or Points of Concern

• Budget Uncertainty: Clients are cautious regarding 2026 budgets, potentially impacting future spending and decision-making processes.
• Policy Changes: Concerns over recent government policies affecting direct-to-consumer advertising could influence pharma budgets and spending patterns.
• Competitive Landscape: Increased competition in the HCP engagement space, with new entrants potentially impacting market share dynamics.

5. Notable Q&A Insights

• Budget Discussions: Management noted uncertainty primarily relates to 2026 budgets, with clients showing caution in finalizing annual budgets.
• AI Strategy: The company plans to fully leverage AI capabilities, with significant growth in AI tools and a focus on optimizing client workflows.
• Health System Engagement: Growth in the health system segment, particularly in enterprise offerings and recruiting solutions, is seen as a long-term growth driver.
• Market Share Dynamics: Doximity continues to grow at approximately 2x the market rate, with expectations to maintain this trajectory despite potential headwinds.

Overall, Doximity reported a strong quarter with impressive financial performance and strategic advancements, though it faces challenges related to budget uncertainties and competitive pressures in the healthcare marketing landscape.